Samjin Pharm (005500.KS)
Samjin Pharmaceuticals Co., Ltd. manufactures and sells medicine. It offers medicine in oral, drop, and injecting forms. The company provides over-the-counter medicines, such as Gevorin, an anti-infalammatory pain killer; Trestan, an appetite stimulant; Flaris, an anti-thrombotic agent; and Nutilin, a brain function improvement agent, as well as medicine for treatment of chronic diseases. It also develops SA001, which is in Phase II clinical trial for the treatment for dry eye syndrome and Sjogren syndrome; SJP1804 medicine that is Phase I clinical trial to treat macular degeneration; and SJP1604, which is in Phase I clinical trial for cancer; SJP1901 and SJP1902 for cancer treatment; SJP 1801 to treat Alzheimer's and Parkinson's disease; SJP006, an anti-viral product; and SJP003 for treatment of diabetes. In addition, the company's preclinical product is SJP1602 for the treatment of cancer. Samjin Pharmaceuticals Co., Ltd. was founded in 1968 and is headquartered in Seoul, South Korea.
Company Info
Highlights
₩221.25B
₩306.65B
₩128.42B
₩15,973.31 - ₩20,576.76
₩24,000.00
Share Price Chart
Loading data...
Compare to other instruments
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
Performance Chart
Loading data...
Returns By Period
Samjin Pharm (005500.KS) returned -0.11% year-to-date (YTD) and -1.46% over the past 12 months. Over the past 10 years, 005500.KS returned -0.86% annually, underperforming the S&P 500 benchmark at 10.85%.
005500.KS
-0.11%
1.23%
0.53%
-1.46%
-7.26%
-5.01%
-0.86%
^GSPC (Benchmark)
0.51%
5.49%
-2.00%
12.02%
12.68%
14.19%
10.85%
Monthly Returns
The table below presents the monthly returns of 005500.KS, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | -4.87% | 1.80% | 0.80% | 1.08% | 1.23% | -0.11% | |||||||
| 2024 | -5.56% | 0.49% | -1.22% | -2.22% | -3.33% | 3.97% | -3.27% | -2.75% | -0.59% | -0.91% | 1.74% | 0.64% | -12.59% |
| 2023 | -6.82% | -5.65% | -5.99% | 7.31% | -1.54% | -1.34% | 1.81% | -0.67% | -0.89% | -4.97% | 4.51% | 1.86% | -12.63% |
| 2022 | -4.94% | 1.00% | -0.00% | -0.20% | 0.40% | -2.37% | -0.20% | 0.61% | 6.05% | -4.18% | 3.37% | 1.57% | 0.60% |
| 2021 | -10.28% | 4.29% | -4.71% | 11.52% | -3.87% | 6.14% | -2.89% | 0.19% | -6.88% | 2.79% | -5.05% | 10.88% | -0.52% |
| 2020 | -5.21% | -4.02% | -1.54% | 13.42% | 9.27% | -2.53% | 5.93% | 2.10% | -1.20% | -10.92% | 11.67% | -2.25% | 12.44% |
| 2019 | -4.73% | 5.88% | -5.80% | 2.36% | -16.77% | -7.69% | -9.50% | -0.92% | -6.32% | 1.79% | -3.12% | 3.62% | -35.87% |
| 2018 | 11.99% | 3.36% | 3.61% | 4.07% | 6.93% | -5.64% | 1.77% | 19.91% | 5.63% | -36.43% | 17.16% | -5.48% | 14.30% |
| 2017 | -7.77% | 4.37% | -2.99% | 4.31% | 3.10% | -5.44% | 1.21% | 0.75% | -2.97% | 1.38% | 10.27% | 0.47% | 5.53% |
| 2016 | 15.48% | -7.64% | 3.23% | 7.03% | 17.88% | 9.29% | -6.23% | -2.87% | 0.31% | -2.02% | 6.96% | 4.92% | 52.53% |
| 2015 | 8.18% | 1.30% | 6.82% | -2.99% | 9.88% | 10.49% | 1.36% | -12.71% | 0.77% | -7.03% | -7.16% | 5.12% | 11.51% |
| 2014 | 13.49% | 3.66% | 5.00% | 4.20% | 3.23% | -2.08% | 1.06% | 7.37% | 18.14% | 5.19% | -12.82% | -0.83% | 51.67% |
Risk-Adjusted Performance
Risk-Adjusted Performance Rank
The current rank of 005500.KS is 38, indicating average performance compared to other stocks on our website. Here’s a breakdown of how it compares using common performance measures.
Risk-Adjusted Performance Indicators
The charts below present risk-adjusted performance metrics for Samjin Pharm (005500.KS) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.
Loading data...
Dividends
Dividend History
Samjin Pharm provided a 4.43% dividend yield over the last twelve months, with an annual payout of ₩800.00 per share. The company has been increasing its dividends for 16 consecutive years.
| Period | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend | ₩800.00 | ₩800.00 | ₩800.00 | ₩800.00 | ₩800.00 | ₩800.00 | ₩800.00 | ₩800.00 | ₩800.00 | ₩700.00 | ₩600.00 | ₩500.00 |
Dividend yield | 4.43% | 4.43% | 3.70% | 3.12% | 3.04% | 2.94% | 3.21% | 1.99% | 2.23% | 2.01% | 2.58% | 2.34% |
Monthly Dividends
The table displays the monthly dividend distributions for Samjin Pharm. The dividends shown in the table have been adjusted to account for any splits that may have occurred.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | |||||||
| 2024 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩800.00 | ₩800.00 |
| 2023 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩800.00 | ₩800.00 |
| 2022 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩800.00 | ₩800.00 |
| 2021 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩800.00 | ₩800.00 |
| 2020 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩800.00 | ₩800.00 |
| 2019 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩800.00 | ₩800.00 |
| 2018 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩800.00 | ₩800.00 |
| 2017 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩800.00 | ₩800.00 |
| 2016 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩700.00 | ₩700.00 |
| 2015 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩600.00 | ₩600.00 |
| 2014 | ₩500.00 | ₩500.00 |
Dividend Yield & Payout
Dividend Yield
Samjin Pharm has a dividend yield of 4.43%, which is quite average when compared to the overall market.
Payout Ratio
Samjin Pharm has a payout ratio of 25.27%, which is quite average when compared to the overall market. This suggests that Samjin Pharm strikes a balance between reinvesting profits for growth and paying dividends to shareholders.
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading data...
Worst Drawdowns
The table below displays the maximum drawdowns of the Samjin Pharm. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Samjin Pharm was 88.86%, occurring on Jun 23, 2004. Recovery took 2550 trading sessions.
The current Samjin Pharm drawdown is 61.24%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -88.86% | Mar 28, 2000 | 1035 | Jun 23, 2004 | 2550 | Oct 10, 2014 | 3585 |
| -75.85% | Oct 29, 1996 | 283 | Dec 23, 1997 | 483 | Dec 6, 1999 | 766 |
| -69.87% | Oct 1, 2018 | 364 | Mar 23, 2020 | — | — | — |
| -46% | Dec 14, 1999 | 11 | Dec 28, 1999 | 26 | Feb 9, 2000 | 37 |
| -37.74% | Aug 20, 1996 | 14 | Sep 6, 1996 | 13 | Sep 25, 1996 | 27 |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading data...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Samjin Pharm over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Earnings Per Share
The chart presents the Earnings Per Share (EPS) performance of Samjin Pharm, comparing actual results with analytics estimates. The company has exceeded analyst expectations for EPS in the past quarter, achieving a 17.4% positive surprise.
Valuation
The Valuation section provides an overview of how Samjin Pharm is priced in the market compared to other companies in the Drug Manufacturers - Specialty & Generic industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PEG Ratio
The chart shows the Price/Earnings to Growth (PEG) ratio for 005500.KS compared to other companies in the Drug Manufacturers - Specialty & Generic industry. 005500.KS currently has a PEG ratio of 0.0. This PEG ratio is low compared to industry peers, which could indicate the stock is undervalued relative to its expected growth.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for 005500.KS relative to other companies in the Drug Manufacturers - Specialty & Generic industry. Currently, 005500.KS has a P/S ratio of 0.8. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for 005500.KS in comparison with other companies in the Drug Manufacturers - Specialty & Generic industry. Currently, 005500.KS has a P/B value of 0.9. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |